AustinPx Capabilities Overview
Join Dave Miller, Chief Scientific Officer at AustinPx, for an overview of the company’s integrated formulation development, analytical, and clinical manufacturing capabilities for complex oral drug programs. The webinar explores AustinPx’s data-driven approach to preformulation, bioavailability enhancement, dosage form development, and speed-to-clinic manufacturing, including its broad ASD technology toolkit and proprietary KinetiSol™ Technology. Real client…
Read MoreAustinPx Live Episode 6: Re-thinking ASD Development: Designing for Scale from Day One
Originally aired on March 18th, 2026 Chief Technology Officer, Chris Brough, Ph.D., will lead a discussion on what it takes to successfully scale amorphous solid dispersions from early development into manufacturing. He will explore common scale-up challenges across ASD technologies, the data and decisions that matter most as programs move toward GMP, and how early…
Read MoreAustinPx Live Episode 5: Re-thinking ASD Development: When Your Molecule Breaks the Rules
Originally aired on January 22nd, 2026 Chief Scientific Officer, Dave Miller, Ph.D., will explore how KinetiSol™ is reshaping the design space for amorphous solid dispersions (ASDs). He’ll break down how our solvent-free platform enables rapid screening, broader excipient use, and higher-performing formulations compared to conventional technologies like spray drying or HME. The session will also…
Read MoreAustinPx Live Episode 4: From Brick Dust to Breakthrough: The Power of Enabled Formulation
Originally aired on October 22nd, 2025 Join us for our fourth episode of AustinPx Live where Chief Scientific Officer, Dave Miller, Ph.D., will share how AustinPx uses enabling formulation strategies to advance molecules once considered too complex to develop. He’ll highlight how our expertise with KinetiSol™, polymer and excipient screening, and biopharm-guided design-of-experiments creates formulations…
Read MoreAustinPx Live Episode 3: From Molecule to Milestone: Fast-Track Formulation
Originally aired on September 25th, 2025 Watch the third session in our AustinPx Live series! Chief Scientific Officer, Dave Miller, Ph.D., will share how AustinPx approaches conventional formulation to accelerate First-in-Human studies without sacrificing scientific rigor. He’ll highlight how our expertise in powder-in-capsule dosing, phase-appropriate analytical support, and early manufacturability considerations helps sponsors navigate tight…
Read MoreAustinPx Live Episode 2: Navigating Complexity: Tailored Analytical & Preclinical Services
Originally aired on August 19th, 2025 In the second session of AustinPx Live, Chief Scientific Officer, Dave Miller, Ph.D., will share how AustinPx designs data-driven, early-phase strategies to solve complex drug development challenges. He’ll highlight our tailored analytical services, preclinical expertise, and how they connect with our broader CDMO model. This 30-minute session includes a…
Read MoreAustinPx Live Episode 1: Inside AustinPx: Live Company Overview
Originally aired on July 9th, 2025 Join us as we kick off our new AustinPx Live series with an inside look at our capabilities. AustinPx’s Chief Scientific Officer, Dave Miller, will walk through who we are, what we do, and how our integrated CDMO services and KinetiSol technology are helping partners overcome complex drug development challenges. This…
Read MoreOvercoming Late Stage Formulations & Manufacturing Challenges with KinetiSol Technology
In this Xtalks webinar, Dr. Dave Miller, Chief Scientific Officer at AustinPx, explores how KinetiSol™ Technology helps sponsors overcome the formulation and manufacturing hurdles that often appear late in development. Traditional spray drying methods can introduce variability, high costs, and scale-up challenges, but KinetiSol offers a solvent-free alternative that delivers consistent performance and improved manufacturability.…
Read MoreDe-Risking Development: Guiding Formulation Strategy with MacroFlux to Predict Human Outcomes of KinetiSol-Processed Etravirine
KinetiSol™ Technology enables formulation of poorly soluble compounds, but predicting human performance remains a key challenge in early development. In this session, Daniel Davis, Ph.D. (Director of Business Development, AustinPx), presents a case study on developing a generic equivalent for Intelence (Etravirine) using MacroFlux™ to establish in-vitro/in-vivo correlation and optimize formulation strategy. By linking dissolution…
Read MoreHow Difficult Is it to Scale Up an Amorphous Dispersion? (Xtalks interview)
In this Xtalks interview, Dr. Justin Keen, Senior Vice President of Operations at AustinPx, explained why scale up is one of the biggest challenges in amorphous dispersion manufacturing and how KinetiSol™ solves it. Traditional technologies like spray drying and hot melt extrusion require controlling multiple transport phenomena at once, which slows timelines and increases cost. KinetiSol…
Read MoreOral Dosage Innovation for Pediatric Drug Delivery
Pediatric drug development isn’t just about reducing adult doses. It involves unique technical, regulatory, and manufacturing challenges that require creative formulation strategies. In this webinar, experts from AustinPx and Via Therapeutics explore the complex development of clofazimine mini-tablets for pediatric use, covering solubility issues, stability hurdles, and process optimization from early formulation through clinical manufacturing.…
Read MoreOptimizing Drug Loading in Amorphous Solid Dispersions: Maximizing Bioavailability While Minimizing Pill Burden
Amorphous solid dispersions (ASDs) have revolutionized drug delivery by enhancing the bioavailability of poorly soluble drugs. However, formulators often assume that higher drug loading in ASDs will automatically reduce pill burden by minimizing excipient content. This approach overlooks a critical factor: increasing the drug-to-polymer ratio can significantly reduce the fraction of drug absorbed, ultimately leading to…
Read MoreOptimizing Amorphous Solid Dispersions: Overcoming Scale-Up Challenges with Next-Generation Technologies
As the number of poorly soluble molecules entering the pipeline has increased, the application of amorphous solid dispersions development has grown. With the advent of next-generation ASD technologies, like KinetiSol Technology, drug developers are setting new standards in scalability, sustainability and performance. In this webinar, the expert speakers will share their scale-up experiences and perspectives on opportunities to…
Read MoreWhy KinetiSol Technology is Disrupting Spray Drying
Dave Miller, AustinPx CSO’s (Chief Scientific Officer) talk begins by showcasing two case studies of commercial spray dried dispersions— replicated with KinetiSol and eliminating toxic solvents, manufacturing complexity, and improving drug product properties. Springboarding from these case studies, Dave then focuses on the facility, utilities, and downstream processing requirements for SDDs and contrasts those with…
Read MoreKinetiSol Technology: Scale-Up Approach
Justin Keen, AustinPx Sr. VP of Operations’ talk begins with a discusion on phase-appropriate process development objectives, reviewed as they relate to scale and mode changes as product development evolves to deliver clinical trial material and develop the process design space. Process parameter and quality attribute relationships, including those for typical pre and post KinetiSol…
Read MoreAmorphous Solid Dispersions: Development Trends, Challenges and the Future
The pharmaceutical industry is pushing the boundaries of the chemical drug space in search of new and more effective compounds. However, many of these new molecules have properties that make them difficult to develop, including challenging physiochemical characteristics. As a result, the number of poorly soluble drugs in the pipeline is increasing, and there is…
Read More